devhealthylife1@gmail.com

Investor Joe Terranova likes Merck despite move to lower Januvia price

Investor Joe Terranova likes Merck despite move to lower Januvia price

Merck could still be a winning stock, despite the pharmaceutical company’s recent move to reprice one of its medications, Virtus Investment Partners chief market strategist Joe Terranova told CNBC’s ” Halftime Report ” on Monday. Terranova suggested he is still bullish on the stock, even after the firm agreed last year to reduce the price of diabetes…

Read More
Oracle’s credit default swaps are plummeting after financing plans

Oracle’s credit default swaps are plummeting after financing plans

Oracle’s 5-year credit default swaps tumbled 17% after the software vendor’s plan to raise $50 billion in debt and equity bolstered investor confidence that the company will be able to avoid a credit downgrade as it funds its artificial intelligence buildout. “Equity financing significantly inhibits the downside for credit,” Andrew Keches, a credit analyst at…

Read More